DBG Health has secured a $1.04 billion minority investment, valuing the business at A$7 billion ($4.56 billion) and securing long-term global growth. WHO: Founded in Melbourne, Australia, by Executive Chair and CEO Dennis Bastas and Executive Director Con Tangalakis, DBG has grown rapidly since acquiring its foundational pharmaceuticals business, Arrow Pharmaceuticals, in 2015. It operates across five core divisions: Arrotex Pharmaceuticals, VidaCorp Consumer Brands, Independent Pharmacies of Australia (IPA), AXE Health Services, and myDNA. Its platform spans prescription medicines, OTC and beauty brands, pharmacy services, and precision health solutions. DBG’s fast-growing beauty and health & wellness division, VidaCorp Consumer Brands, includes MCoBeauty, Chemists Own, Ferro-grad C, Nude by Nature, Poni Cosmetics, Sunskills, Lip Heros, and Skinb5.Founded in 2023, BDT & MSD Partners is a merchant bank with an advisory and investment platform built to serve the distinct needs of business owners and strategic, long-term investors. The firm is distinguished by its decades of experience advising at the intersection of founders, families, and businesses, as well as by its differentiated capital base and culture of aligned investing.WHY: Starting in 2026, the biggest part of the add-on investment of $1 billion will be used to pursue international acquisition opportunities that would benefit from sitting on the platform's scale and the partnerships created with retail partners.IN THEIR OWN WORDS: Dennis Bastas said, “In bringing in outside capital, we were deliberate in choosing a partner who shares our founder-led business efforts and long-term focus.